Journal of clinical oncology, 2022-01, Vol.40 (3), p.307-309
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update
- Ist Teil von
- Journal of clinical oncology, 2022-01, Vol.40 (3), p.307-309
- Ort / Verlag
- United States
- Erscheinungsjahr
- 2022
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0732-183XeISSN: 1527-7755DOI: 10.1200/JCO.21.02677Titel-ID: cdi_proquest_miscellaneous_2608452322
- Format
- –
- Schlagworte
- Aminopyridines - adverse effects, Aminopyridines - therapeutic use, Antineoplastic Agents, Hormonal - adverse effects, Antineoplastic Agents, Hormonal - therapeutic use, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Benzimidazoles - adverse effects, Benzimidazoles - therapeutic use, Breast Neoplasms - drug therapy, Breast Neoplasms - mortality, Breast Neoplasms - pathology, Chemotherapy, Adjuvant, Consensus, Disease-Free Survival, Female, Humans, Medical Oncology - standards, Neoplasm Staging, Protein Kinase Inhibitors - adverse effects, Protein Kinase Inhibitors - therapeutic use, Time Factors